Conexeu Sciences Inc. Common Stock (CNXU) - Total Assets
Based on the latest financial reports, Conexeu Sciences Inc. Common Stock (CNXU) holds total assets worth $8.20 Million USD as of April 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how liquid is Conexeu Sciences Inc. Common Stock's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Conexeu Sciences Inc. Common Stock - Total Assets Trend (2024–2025)
This chart illustrates how Conexeu Sciences Inc. Common Stock's total assets have evolved over time, based on quarterly financial data.
Conexeu Sciences Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (October 2025)
Conexeu Sciences Inc. Common Stock's total assets of $8.20 Million consist of 97.0% current assets and 3.0% non-current assets. Also see CNXU stock market capitalisation for the company's overall valuation and market capitalisation.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 62.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $176.88K | 2.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2024–2025)
This chart illustrates how Conexeu Sciences Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See CNXU stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Conexeu Sciences Inc. Common Stock's current assets represent 97.0% of total assets in 2025, an increase from 65.0% in 2024.
- Cash Position: Cash and equivalents constituted 62.6% of total assets in 2025, up from 58.9% in 2024.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 34.0% in 2024.
- Asset Diversification: The largest asset category is intangible assets at 2.3% of total assets.
Conexeu Sciences Inc. Common Stock Competitors by Total Assets
Key competitors of Conexeu Sciences Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Stayble Therapeutics AB
ST:STABL
|
Sweden | Skr8.62 Million |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €2.00 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.42 Billion |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
|
China | CN¥3.25 Billion |
Conexeu Sciences Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.89 | 8.51 | - |
| Quick Ratio | 7.89 | 8.51 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | $6.91 Million | $6.58 Million | - |
Conexeu Sciences Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Conexeu Sciences Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 26.96 |
| Latest Market Cap to Assets Ratio | 27.74 |
| Asset Growth Rate (YoY) | 1340.0% |
| Total Assets | $7.69 Million |
| Market Capitalization | $213.26 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Conexeu Sciences Inc. Common Stock's assets at a significant premium (27.74x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Conexeu Sciences Inc. Common Stock's assets grew by 1340.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Conexeu Sciences Inc. Common Stock (2024–2025)
The table below shows the annual total assets of Conexeu Sciences Inc. Common Stock from 2024 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-10-31 | $7.69 Million | +1340.00% |
| 2024-10-31 | $533.94K | -- |
About Conexeu Sciences Inc. Common Stock
Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, b… Read more